Alto Neuroscience (NYSE:ANRO) Price Target Raised to $37.00

Alto Neuroscience (NYSE:ANRO) had its target price lifted by BTIG Research from $28.00 to $37.00 in a report released on Thursday, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the stock.

A number of other brokerages have also issued reports on ANRO. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Robert W. Baird reduced their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Wolfe Research assumed coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Bank of America began coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Zacks Research downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.62.

Alto Neuroscience Stock Down 0.5%

Shares of NYSE:ANRO opened at $32.14 on Thursday. The company has a quick ratio of 20.52, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average of $25.97 and a two-hundred day moving average of $22.75. The stock has a market cap of $1.13 billion, a P/E ratio of -13.28 and a beta of 1.06. Alto Neuroscience has a 52-week low of $3.05 and a 52-week high of $33.67.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. On average, research analysts expect that Alto Neuroscience will post -3 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP lifted its position in shares of Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after purchasing an additional 490 shares in the last quarter. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the fourth quarter valued at approximately $62,000. XTX Topco Ltd grew its holdings in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after purchasing an additional 6,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Alto Neuroscience by 26.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after buying an additional 8,148 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.